Personalised medicine

One stumbling block to personalised medicine is the upfront investment. Research for Science|Business is published in a peer-reviewed journal quantifying potential savings from a tailored programme of exercise, diagnostics and telemonitoring for heart care.

A year after Science|Business highlighted the hurdles that stand in the way of deploying personalised medicine there has been progress, even if some barriers remain in place

Index Ventures raised $400 million dollars in its last fund, of which about half will be invested in life science start-ups. Senior partner, Francesco de Rubertis says personalised medicine will take a large share of this.

The UK Technology Strategy Board has set up the Stratified Medicines Innovation Platform to oversee an investment of over £50 million in personalised medicine.